Review summary
Teaching objective: Diagnose and treat sarcoidosis with cardiac involvement in a 52-year-old Black woman and touring singer, in whom sarcoidosis is more common and more often severe and fatal than in White Americans, on the ATS 2020 diagnosis guideline, the ERS 2021 treatment guideline, the HRS 2014 cardiac sarcoidosis consensus and the AHA 2024 scientific statement: chest imaging with bilateral hilar adenopathy; pulmonary function with DLCO; EBUS-guided lymph node aspiration showing non-necrotizing granulomas, with tuberculosis and fungal infection excluded; screening every patient for other organ involvement (eye examination, ECG, calcium and vitamin D handling, liver and kidney tests); cardiac evaluation with ECG, Holter monitoring, echocardiography, cardiac MRI and FDG-PET before treatment begins; prednisone with methotrexate as a steroid-sparing agent, with methotrexate safety monitoring; bone protection that avoids calcium supplements while calcium is high; pneumocystis prophylaxis, vaccination and tuberculosis screening before immunosuppression; arrhythmia risk stratification with electrophysiology study and a defibrillator; and a plan that protects her voice, her performing and her travel.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| October 26, 1911 | Born in New Orleans. | CLM-0001 |
| 1928 | Moves to Chicago and joins the Greater Salem Baptist Church. | CLM-0002 |
| October 4, 1950 | Carnegie Hall debut. | CLM-0002, CLM-0004 |
| 1952 | First European tour, sung in pain with breathlessness, then cancelled; hysterectomy, with granulomas found and sarcoidosis diagnosed. | CLM-0005 |
| August 28, 1963 | Sings at the March on Washington. | CLM-0003 |
| 1964 to 1965 | Admitted in Chicago after a coughing spell (month not recorded); told privately of a heart attack and sarcoidosis in her heart; a year of recovery without touring. | CLM-0006, CLM-0012 |
| Fall 1967 | Hospitalized for heart trouble. | CLM-0007 |
| 1968 | Cuts short a European tour; eye inflammation and cramps in her legs and hands. | CLM-0008 |
| 1971 | Tours Japan, India and Europe; falls ill in Germany after her last concert, in Munich, and is hospitalized at home. | CLM-0009 |
| January 27, 1972 | Dies at Little Company of Mary Hospital in Evergreen Park, Illinois, at 60. | CLM-0010, CLM-0011 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Mahalia Jackson was born in New Orleans on October 26, 1911, the third of six children of a man who was a longshoreman by day, a barber by night and a clergyman on Sunday. Her mother died when she was six, and she was raised by an aunt in a poor but respectable home; she left school in the eighth grade to work as a cook and washerwoman. | confirmed | Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports HISTMED Master Roster v3 context |
| D | In 1928 she moved to Chicago, worked as a hotel maid and laundress, and joined the Greater Salem Baptist Church, where she became a soloist. She never learned to read music. After her Carnegie Hall debut on October 4, 1950, she began touring abroad in 1952, and toured widely for the rest of her life. Her life as a touring singer anchors the modern social history and the plan built around her performing and travel. |
confirmed | Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports Mahalia Jackson (This Far by Faith) supports |
| D | She was closely associated with the civil rights movement and sang at the March on Washington in 1963 before Dr. Martin Luther King Jr.'s speech. When she moved into an all-white neighborhood on the South Side of Chicago, a bullet was fired through a window of her home. Anchors the modern social history: a singer whose work was bound up with the civil rights movement, who met racist violence at home. |
confirmed | Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports |
| D | Touring the segregated South for as many as 200 dates a year, she and her company had trouble finding safe places to sleep, eat and buy gas, sometimes slept in her car, lived on bags of fruit and drove half the night, and she arrived so exhausted she was almost dizzy when she sang; she insisted on being paid in cash because checks were often refused. Context for the modern social history; the details come from a tertiary summary of her autobiography and Goreau's biography. |
probable | Mahalia Jackson supports Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports |
| D | Before and during her first European tour in 1952 she had difficulty breathing during and after performances and severe abdominal cramping, sang many shows in pain, lost a great deal of weight and finally cancelled the tour. On her return she had a hysterectomy, at which numerous granulomas were found in her abdomen, and she was diagnosed with sarcoidosis. From then on she had occasional bouts of fatigue and shortness of breath that became more frequent as her schedule filled. The anchor for the modern presenting problem and the past history. The account rests on Goreau's biography as summarized by Wikipedia and on TheWrap; no pathology record was found. |
probable | Mahalia Jackson supports Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports |
| D | In 1964, weeks after her marriage, she could not stop coughing on the drive home from a concert in St. Louis and admitted herself to a Chicago hospital. The diagnosis given in public was heart strain and exhaustion; her doctors told her privately that she had had a heart attack and that sarcoidosis was now in her heart. Recovery took a year, during which she could not tour or record and lost about 50 pounds; afterwards she had near-constant fatigue, bouts of tachycardia and high blood pressure. From 1964 she was in and out of hospitals, and physicians warned her of exhaustion from her itineraries. The documented cardiac illness to which the modern diagnosis of cardiac sarcoidosis is linked. The account of what her doctors told her privately comes from Goreau's biography as summarized by Wikipedia. |
probable | Mahalia Jackson supports Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports |
| D | She was hospitalized for heart trouble in the fall of 1967. Documented heart illness after the index date. |
confirmed | Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports |
| D | By the late 1960s she had inflammation in her eyes and painful cramps in her legs and hands; she cut short a European tour in 1968 for health reasons. Documented symptoms after the index date; that the eye inflammation was sarcoid uveitis is not stated in the sources. |
probable | Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports Mahalia Jackson supports |
| D | In 1971 she toured Japan, India and Europe; she became ill on tour in Germany, where she gave her last concert in Munich, and was flown home to Chicago and hospitalized in the fall. Documented final illness; history only. |
confirmed | Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports Mahalia Jackson supports Mahalia Jackson Theater for the Performing Arts supports Mahalia Jackson supports |
| D | She died on January 27, 1972, at Little Company of Mary Hospital in Evergreen Park, Illinois, at 60, after several years of poor health. The documented death. History only, stated without detail. |
confirmed | Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports Nixon R. Statement on the Death of Mahalia Jackson (January 27, 1972) supports |
| R | The cause of her death is recorded differently: a heart seizure (The New York Times), heart failure (PBS), a heart attack (Biography.com), heart complications at home (New Orleans Historical), and death in recovery after surgery for a bowel obstruction, which one account attributes to sarcoidosis (Wikipedia, TheWrap). Retrospective; the accounts conflict, and none gives a medical record. The modern episode does not resolve the question. |
disputed | Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) supports Mahalia Jackson (This Far by Faith) supports Mahalia Jackson supports Mahalia Jackson Theater for the Performing Arts supports Mahalia Jackson supports Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed supports |
| R | That her heart disease, and the heart trouble that recurred until her death, was cardiac sarcoidosis is a retrospective interpretation. It rests on the private account of her doctors in 1964 reported by her biographer; the public diagnoses were heart strain, exhaustion and heart trouble. Retrospective interpretation linked to the modern cardiac sarcoidosis problem; it is not a confirmed historical diagnosis. |
possible | Mahalia Jackson supports Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) context |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excluded | resolved | confirmed | active | CLM-0005 |
| S | Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked for | resolved | confirmed | active | CLM-0005 |
| S | Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raised | resolved | confirmed | active | CLM-0005 |
| S | Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosis | active | confirmed | both_with_link | CLM-0005, CLM-0006 |
| S | Acute viral laryngitis: three days of hoarseness, a sore throat and a mild dry cough after a cold, without fever, on prednisone 20 mg and methotrexate; rapid influenza and COVID-19 tests negative; no thrush; resolved | resolved | confirmed | active | |
| S | Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heart | active | confirmed | both_with_link | CLM-0006, CLM-0012 |
| S | Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manage | active | confirmed | active | |
| S | Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoring | active | confirmed | active | CLM-0006, CLM-0012 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-02-09 | Hemoglobin [Mass/volume] in Blood | 12.4 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-02-09 | Leukocytes [#/volume] in Blood by Automated count | 4.6 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-02-09 | Lymphocytes [#/volume] in Blood by Automated count | 0.9 10*3/uL (low) Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 2026-02-09 | Platelets [#/volume] in Blood by Automated count | 232 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-02-09 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-02-09 | Potassium [Moles/volume] in Serum or Plasma | 4.1 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-02-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 mg/dL (high) Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-02-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 62 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-02-09 | Glucose [Mass/volume] in Serum or Plasma | 104 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-02-09 | Calcium [Mass/volume] in Serum or Plasma | 10.8 mg/dL (high) Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-02-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-02-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-02-09 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 128 U/L (high) Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 2026-02-09 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-02-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9% (high) Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes |
http://loinc.org · 4548-4 |
| S | 2026-02-09 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-02-09 | 1,25-Dihydroxyvitamin D [Mass/volume] in Serum or Plasma | 84 pg/mL (high) Reference 18-72 pg/mL |
http://loinc.org · 62290-2 |
| S | 2026-02-09 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 210 pg/mL (high) Reference <=125 pg/mL |
http://loinc.org · 33762-6 |
| S | 2026-02-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 mIU/L Reference 0.4-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-02-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 2026-02-23 | FVC measured/predicted | 74% (low) Reference >=80% |
http://loinc.org · 19872-1 |
| S | 2026-02-23 | FEV1 measured/predicted | 76% (low) Reference >=80% |
http://loinc.org · 20152-5 |
| S | 2026-02-23 | FEV1/FVC | 80% Reference >=70% |
http://loinc.org · 19926-5 |
| S | 2026-02-23 | Diffusion capacity.carbon monoxide/Predicted | 62% (low) Reference >=80% |
http://loinc.org · 98130-8 |
| S | 2026-02-23 | Calcium [Mass/volume] in Serum or Plasma | 10.7 mg/dL (high) Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-02-23 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-02-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 65 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-02-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-09 | Leukocytes [#/volume] in Blood by Automated count | 4.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-03-09 | Lymphocytes [#/volume] in Blood by Automated count | 0.9 10*3/uL (low) Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 2026-03-09 | Platelets [#/volume] in Blood by Automated count | 240 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 66 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-09 | Glucose [Mass/volume] in Serum or Plasma | 101 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-03-09 | Calcium [Mass/volume] in Serum or Plasma | 10.6 mg/dL (high) Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-03-09 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 124 U/L (high) Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 2026-03-09 | Albumin [Mass/volume] in Serum or Plasma | 4 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-03-09 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 240 pg/mL (high) Reference <=125 pg/mL |
http://loinc.org · 33762-6 |
| S | 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 2026-05-11 | Hemoglobin [Mass/volume] in Blood | 13.1 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-05-11 | Leukocytes [#/volume] in Blood by Automated count | 9.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-05-11 | Lymphocytes [#/volume] in Blood by Automated count | 1.2 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 2026-05-11 | Platelets [#/volume] in Blood by Automated count | 262 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-05-11 | Potassium [Moles/volume] in Serum or Plasma | 3.9 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 75 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-05-11 | Glucose [Mass/volume] in Serum or Plasma | 118 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-05-11 | Calcium [Mass/volume] in Serum or Plasma | 9.6 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-05-11 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-05-11 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 U/L Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 2026-05-11 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-05-11 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.3% (high) Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes |
http://loinc.org · 4548-4 |
| S | 2026-05-11 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-05-11 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 140 pg/mL (high) Reference <=125 pg/mL |
http://loinc.org · 33762-6 |
| S | 2026-05-11 | FVC measured/predicted | 84% Reference >=80% |
http://loinc.org · 19872-1 |
| S | 2026-05-11 | FEV1 measured/predicted | 85% Reference >=80% |
http://loinc.org · 20152-5 |
| S | 2026-05-11 | FEV1/FVC | 80% Reference >=70% |
http://loinc.org · 19926-5 |
| S | 2026-05-11 | Diffusion capacity.carbon monoxide/Predicted | 70% (low) Reference >=80% |
http://loinc.org · 98130-8 |
| S | 2026-05-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 2026-08-24 | Hemoglobin [Mass/volume] in Blood | 13 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-08-24 | Leukocytes [#/volume] in Blood by Automated count | 8.1 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-08-24 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 10*3/uL Reference 1-4.8 10*3/uL |
http://loinc.org · 731-0 |
| S | 2026-08-24 | Platelets [#/volume] in Blood by Automated count | 248 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-08-24 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-08-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 77 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-08-24 | Glucose [Mass/volume] in Serum or Plasma | 108 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-08-24 | Calcium [Mass/volume] in Serum or Plasma | 9.5 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-08-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 2026-08-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 U/L Reference 8-35 U/L |
http://loinc.org · 1920-8 |
| S | 2026-08-24 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 90 U/L Reference 35-104 U/L |
http://loinc.org · 6768-6 |
| S | 2026-08-24 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 2026-08-24 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.2% (high) Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes |
http://loinc.org · 4548-4 |
| S | 2026-08-24 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 ng/mL Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-08-24 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 96 pg/mL Reference <=125 pg/mL |
http://loinc.org · 33762-6 |
| S | 2026-08-24 | FVC measured/predicted | 90% Reference >=80% |
http://loinc.org · 19872-1 |
| S | 2026-08-24 | FEV1 measured/predicted | 89% Reference >=80% |
http://loinc.org · 20152-5 |
| S | 2026-08-24 | FEV1/FVC | 79% Reference >=70% |
http://loinc.org · 19926-5 |
| S | 2026-08-24 | Diffusion capacity.carbon monoxide/Predicted | 76% (low) Reference >=80% |
http://loinc.org · 98130-8 |
| S | 2026-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-10-05 | Cholesterol [Mass/volume] in Serum or Plasma | 204 mg/dL (high) Reference <=200 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-10-05 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 mg/dL Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-10-05 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 126 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-10-05 | Triglyceride [Mass/volume] in Serum or Plasma | 118 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-02-09 | Body height | 170 cm | 8302-2 | S |
| 2026-02-09 | Body weight | 92 kg | 29463-7 | S |
| 2026-02-09 | Body mass index (BMI) [Ratio] | 31.8 kg/m2 | 39156-5 | S |
| 2026-02-09 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-02-09 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-02-09 | Heart rate | 86 /min | 8867-4 | S |
| 2026-02-09 | Respiratory rate | 18 /min | 9279-1 | S |
| 2026-02-09 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 % | 59408-5 | S |
| 2026-02-23 | Body height | 170 cm | 8302-2 | S |
| 2026-02-23 | Body weight | 91.6 kg | 29463-7 | S |
| 2026-02-23 | Body mass index (BMI) [Ratio] | 31.7 kg/m2 | 39156-5 | S |
| 2026-02-23 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-02-23 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-02-23 | Heart rate | 82 /min | 8867-4 | S |
| 2026-02-23 | Respiratory rate | 18 /min | 9279-1 | S |
| 2026-02-23 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 % | 59408-5 | S |
| 2026-03-09 | Body height | 170 cm | 8302-2 | S |
| 2026-03-09 | Body weight | 91.2 kg | 29463-7 | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 31.6 kg/m2 | 39156-5 | S |
| 2026-03-09 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-03-09 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-03-09 | Heart rate | 80 /min | 8867-4 | S |
| 2026-03-09 | Respiratory rate | 18 /min | 9279-1 | S |
| 2026-03-09 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 % | 59408-5 | S |
| 2026-05-11 | Body height | 170 cm | 8302-2 | S |
| 2026-05-11 | Body weight | 94 kg | 29463-7 | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 32.5 kg/m2 | 39156-5 | S |
| 2026-05-11 | Systolic blood pressure | 138 mm[Hg] | 8480-6 | S |
| 2026-05-11 | Diastolic blood pressure | 86 mm[Hg] | 8462-4 | S |
| 2026-05-11 | Heart rate | 66 /min | 8867-4 | S |
| 2026-05-11 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-05-11 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-08-24 | Body height | 170 cm | 8302-2 | S |
| 2026-08-24 | Body weight | 93 kg | 29463-7 | S |
| 2026-08-24 | Body mass index (BMI) [Ratio] | 32.2 kg/m2 | 39156-5 | S |
| 2026-08-24 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 2026-08-24 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 2026-08-24 | Heart rate | 64 /min | 8867-4 | S |
| 2026-08-24 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-08-24 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-06-15 | Body height | 170 cm | 8302-2 | S |
| 2026-06-15 | Body weight | 93.4 kg | 29463-7 | S |
| 2026-06-15 | Body mass index (BMI) [Ratio] | 32.3 kg/m2 | 39156-5 | S |
| 2026-06-15 | Systolic blood pressure | 134 mm[Hg] | 8480-6 | S |
| 2026-06-15 | Diastolic blood pressure | 84 mm[Hg] | 8462-4 | S |
| 2026-06-15 | Heart rate | 72 /min | 8867-4 | S |
| 2026-06-15 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-06-15 | Body temperature | 37.4 Cel | 8310-5 | S |
| 2026-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 2026-10-05 | Body height | 170 cm | 8302-2 | S |
| 2026-10-05 | Body weight | 92.2 kg | 29463-7 | S |
| 2026-10-05 | Body mass index (BMI) [Ratio] | 31.9 kg/m2 | 39156-5 | S |
| 2026-10-05 | Systolic blood pressure | 128 mm[Hg] | 8480-6 | S |
| 2026-10-05 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 2026-10-05 | Heart rate | 66 /min | 8867-4 | S |
| 2026-10-05 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-10-05 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Gospel singer who tours in the United States and abroad, with concerts of two to three hours several times a week, recording sessions, and singing at her church in Chicago; travels by car and air; reads no music and sings by ear
- S Lives in her own house on the South Side of Chicago; has no children; an extended family and a large church community; travels with her pianist and a small company. No relative, companion or colleague is named or given a role in her care
- S Has known racism on the road and at home; long drives between concerts, irregular meals, and little rest on tour; wants her doctors to understand that singing is her calling and her living
- S Never smoker; no alcohol; no drug use; faith central to her life
- S Hysterectomy at 40; no periods since; no menopausal hormone therapy
Functional status
- S Independent; climbs one flight of stairs before stopping for breath; has shortened her concerts by half an hour
Mental status
- S Warm, forthright and tired; worried that she will have to stop singing; PHQ-2 negative; no thoughts of self-harm
Allergies and medications
Allergies
- S No known allergy
Medications
- S Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning
- S Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks
- S Prednisone 20 mg oral tablet, one tablet (20 mg) by mouth each morning for four weeks
- S Prednisone 5 mg oral tablet, three tablets (15 mg) by mouth each morning for four weeks
- S Prednisone 10 mg oral tablet, one tablet (10 mg) by mouth each morning
- S Prednisone 5 mg oral tablet, one and a half tablets (7.5 mg) by mouth each morning
- S Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays
- S Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays
- S Folic acid 1 mg oral tablet, one tablet by mouth daily
- S Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food
- S Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutes
- S Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily
- S Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth daily
Procedures and immunizations
Procedures
- S Chest radiograph, two views: bilateral symmetric hilar lymph node enlargement with right paratracheal widening and fine reticulonodular opacities in both upper zones; heart size normal; no effusion
- S Resting 12-lead ECG: sinus rhythm 84 per minute, PR interval 240 ms (first-degree atrioventricular block), QRS 100 ms, frequent unifocal ventricular ectopic beats; no Q waves; no previous ECG for comparison
- S High-resolution CT of the chest: symmetric hilar, subcarinal and right paratracheal lymph nodes up to 2.4 cm, some with fine calcification; perilymphatic micronodules along the bronchovascular bundles and fissures in both upper lobes; no fibrosis, traction bronchiectasis or mass
- S Endobronchial ultrasound-guided transbronchial needle aspiration of lymph node stations 4R, 7 and 11L under moderate sedation, with bronchoalveolar lavage: non-necrotizing granulomas at all three stations; acid-fast and fungal stains negative; mycobacterial and fungal cultures sent; lavage lymphocytes 32 percent with a CD4 to CD8 ratio of 5.2; no malignant cells
- S Advance care planning conversation, about 30 minutes, including her wishes about the defibrillator
- S Full pulmonary function tests (spirometry, lung volumes and diffusing capacity): FVC 74 percent, FEV1 76 percent of predicted, FEV1/FVC 80 percent, total lung capacity 78 percent, DLCO 62 percent of predicted: mild restriction with a reduced diffusing capacity
- S 24-hour Holter monitoring: sinus rhythm 58 to 112 per minute; PR interval 230 to 250 ms throughout; ventricular ectopic beats 6 percent of all beats, unifocal; three runs of nonsustained ventricular tachycardia of up to 8 beats; no second- or third-degree atrioventricular block; palpitations recorded during a run of ectopic beats
- S Transthoracic echocardiogram: left ventricular ejection fraction 47 percent with thinning and hypokinesis of the basal anteroseptum; normal right ventricle; normal valves; estimated pulmonary artery systolic pressure 28 mmHg; no pericardial effusion
- S Cardiac MRI with late gadolinium enhancement: left ventricular ejection fraction 47 percent; patchy mid-wall and subepicardial enhancement of the basal anteroseptum and inferolateral wall (about 9 percent of left ventricular mass), with raised T2 signal in the basal septum; right ventricle normal
- S Dilated eye examination by ophthalmology: no anterior or posterior uveitis, no conjunctival nodules, intraocular pressure 15 and 16 mmHg, no cataract
- S Cardiac FDG-PET with perfusion imaging, after 72 hours of a high-fat, very-low-carbohydrate diet and an overnight fast: focal FDG uptake in the basal anteroseptum and lateral wall (maximum SUV 6.2) matching the MRI enhancement, with a mild perfusion defect at the same sites; FDG-avid hilar and mediastinal lymph nodes; no uptake elsewhere outside the chest
- S Bone density scan (DXA): lumbar spine T-score -1.2, femoral neck T-score -1.6; FRAX adjusted for prednisone of 7.5 mg or more: major osteoporotic fracture 9 percent and hip fracture 1.2 percent at ten years (moderate risk)
- S Electrophysiology study: HV interval 58 ms; sustained monomorphic ventricular tachycardia (220 per minute) induced with double extrastimuli from the right ventricular apex, ended by overdrive pacing
- S Implantation of a dual-chamber transvenous cardioverter-defibrillator through the left subclavian vein, programmed with ventricular tachycardia therapies and minimal ventricular pacing; enrolled in remote monitoring; no complications
- S Repeat spirometry and diffusing capacity after nine weeks of treatment: FVC 84 percent and FEV1 85 percent of predicted, FEV1/FVC 80 percent, DLCO 70 percent of predicted
- S Repeat cardiac FDG-PET with the same preparation after five months of treatment: no myocardial FDG uptake; perfusion normal; hilar and mediastinal nodes smaller with low uptake
- S Repeat transthoracic echocardiogram: left ventricular ejection fraction 54 percent; basal septal thinning unchanged; normal right ventricle
- S Repeat spirometry and diffusing capacity after six months of treatment: FVC 90 percent and FEV1 89 percent of predicted, FEV1/FVC 79 percent, DLCO 76 percent of predicted
Immunizations
- S 2020-11-16: Tdap vaccine
- S 2026-02-09: Influenza vaccine, this season (inactivated), late in the season
- S 2026-03-09: Pneumococcal conjugate vaccine (PCV20), before immunosuppression
- S 2026-03-09: Recombinant zoster vaccine, dose 1 of 2
- S 2026-03-09: Hepatitis B vaccine (adjuvanted, two-dose series), dose 1
- S 2026-05-11: Hepatitis B vaccine (adjuvanted, two-dose series), dose 2
- S 2026-08-24: Recombinant zoster vaccine, dose 2 of 2
- S 2026-10-05: Influenza vaccine, this season (inactivated)
- S 2026-10-05: COVID-19 mRNA vaccine, this season's formula
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1952: Breathlessness and abdominal cramping during a concert tour abroad at 40, with weight loss and a cancelled tour; hysterectomy afterwards, at which granulomas were reported in the abdomen and sarcoidosis was diagnosed; no pathology report available (CLM-0005)
Family history
- D mother: Died when she was six; cause not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation | 2026-03-09 | completed | EBUS in nine days; eye examination, Holter, echocardiogram, cardiac MRI and FDG-PET within four weeks |
| Calcium in the normal range within three months | 2026-05-11 | completed | Calcium 9.6 mg/dL after nine weeks of treatment |
| FVC and DLCO improved by at least 10 percent of predicted within six months | 2026-08-24 | completed | FVC 74 to 90 percent and DLCO 62 to 76 percent of predicted |
| No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better | 2026-08-24 | completed | Myocardial uptake resolved; ejection fraction 54 percent from 47 |
| Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent | 2026-08-24 | completed | Prednisone 10 mg at six months and tapering |
| Back on stage with a schedule she can sustain, with her voice protected | 2026-08-24 | completed | Two concerts a week since late spring; a longer autumn tour planned |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Pulmonology (sarcoidosis) consultation within two weeks, with EBUS-guided lymph node sampling arranged directly from the referral, to confirm the diagnosis and plan treatment | completed | GL-ATS-SARC-2020, GL-ERS-SARC-2021 |
| Diagnosis of suspected sarcoidosis: chest radiograph and CT of the chest, tissue by EBUS-guided needle aspiration rather than mediastinoscopy, stains and cultures for mycobacteria and fungi, an interferon-gamma release assay and HIV test to exclude other causes; serum ACE is not used to make or exclude the diagnosis | completed | GL-ATS-SARC-2020 |
| Screening every patient with suspected sarcoidosis for other organ involvement: ECG, serum calcium with 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, creatinine, liver tests and alkaline phosphatase, complete blood count, TSH, and an eye examination; stop the calcium and vitamin D supplement while calcium is high | completed | GL-ATS-SARC-2020 |
| Cardiac evaluation for suspected cardiac sarcoidosis (abnormal ECG and palpitations): 24-hour Holter monitoring, echocardiogram, cardiac MRI with late gadolinium enhancement, and cardiac FDG-PET with a dietary preparation, all before glucocorticoids begin; cardiology and electrophysiology review | completed | GL-HRS-CS-2014, GL-AHA-CS-2024, GL-ATS-SARC-2020 |
| Treatment of cardiac and pulmonary sarcoidosis: prednisone 40 mg daily, tapered over about six months toward 5 to 10 mg, with methotrexate 15 mg weekly (increased to 20 mg) and folic acid, continued for at least a year for cardiac disease; repeat FDG-PET after about six months | completed | GL-ERS-SARC-2021, GL-AHA-CS-2024, GL-HRS-CS-2014 |
| Methotrexate safety: hepatitis B and C screening before starting, blood count, liver tests and creatinine every two to four weeks for the first three months and then every eight to twelve weeks, no alcohol, and no trimethoprim-sulfamethoxazole while on methotrexate | completed | GL-ACR-DMARD-2012, GL-ERS-SARC-2021 |
| Glucocorticoid protection: bone density scan and FRAX, alendronate weekly, dietary calcium only (no supplements while calcium was high), vitamin D replaced cautiously once calcium is normal, with calcium rechecked; atovaquone pneumocystis prophylaxis while prednisone is 20 mg or more with methotrexate; glucose, blood pressure, weight, mood, sleep and eye pressure checks | completed | GL-ACR-GIOP-2022, GL-CMID-2026, GL-ERS-SARC-2021 |
| Vaccination before immunosuppression: PCV20, recombinant zoster vaccine, hepatitis B vaccine for a non-immune adult, influenza and COVID-19 vaccines; no live vaccines while on prednisone and methotrexate | completed | GL-CDC-IMZ-2026 |
| Arrhythmia risk: metoprolol for ventricular ectopy; electrophysiology study for a left ventricular ejection fraction above 35 percent with scar on MRI and nonsustained ventricular tachycardia, and a dual-chamber defibrillator if sustained ventricular tachycardia is induced; remote device monitoring, including on tour | completed | GL-HRS-CS-2014, GL-AHA-CS-2024 |
| Performing and travel: concerts paused until the defibrillator wound has healed and the first device check is done, then a lighter schedule with rest days, voice care, and a travel letter with her device card and medicine list; no driving for one week after the implant | completed | GL-HRS-CS-2014, GL-ERS-SARC-2021 |
| Depression screening at each phase, plain explanations with written information, and support she chooses; she decides who receives each note | completed | GL-USPSTF-DEP-2023 |
Planned encounters
- 2026-02-09 — Three months of breathlessness, cough, tiredness and palpitations in a touring singer of 52: examination, chest radiograph, ECG and blood tests (ENC-001)
- 2026-02-23 — EBUS result: sarcoidosis; pulmonology consultation, lung function, screening for other organ involvement, and cardiac tests (ENC-002)
- 2026-03-09 — Cardiac MRI and FDG-PET results: cardiac sarcoidosis; start of prednisone and methotrexate, bone and infection protection, and electrophysiology referral (ENC-003)
- 2026-05-11 — Nine weeks of treatment: lung function, calcium, methotrexate safety, the new defibrillator, steroid effects, and her concert schedule (ENC-004)
- 2026-06-15 — Same-day sick visit for laryngitis on immunosuppressive treatment (ENC-006, unscheduled)
- 2026-08-24 — Six months of treatment: repeat FDG-PET, steroid taper, and plans for touring (ENC-005)
- 2026-10-05 — Periodic adult preventive visit (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Sick Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Preventive Visit
- Pulmonology (sarcoidosis) referral
- Pulmonology (sarcoidosis) consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Sick Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Preventive Visit (XML)
- Pulmonology (sarcoidosis) referral (XML)
- Pulmonology (sarcoidosis) consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Whitman A. Mahalia Jackson, Gospel Singer, And a Civil Rights Symbol, Dies (The New York Times obituary, January 28, 1972) | The New York Times (On This Day archive) | other |
| SRC-0002 | Nixon R. Statement on the Death of Mahalia Jackson (January 27, 1972) | The American Presidency Project, University of California, Santa Barbara | other |
| SRC-0003 | Mahalia Jackson (This Far by Faith) | PBS | other |
| SRC-0004 | Mahalia: 4 Key Facts About Mahalia Jackson's Life the Lifetime Movie Missed | TheWrap | other |
| SRC-0005 | Mahalia Jackson | Wikipedia | other |
| SRC-0006 | Mahalia Jackson | Biography.com (A&E Television Networks) | other |
| SRC-0007 | HISTMED Master Roster v3 | The Human Record project | other |
| SRC-0008 | Mahalia Jackson Theater for the Performing Arts | New Orleans Historical (University of New Orleans) | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the diagnosis by EBUS with infection excluded, the decision to complete cardiac MRI and FDG-PET before glucocorticoids, the prednisone dose and taper with methotrexate, the defibrillator decision after an inducible electrophysiology study with an ejection fraction of 47 percent, the handling of calcium and vitamin D with alendronate, atovaquone instead of trimethoprim-sulfamethoxazole with methotrexate, and the touring plan. |
| provenance review | not_started | She died in 1972; the recent-death rule does not apply. Claims rest on The New York Times obituary, the presidential statement, PBS, Biography.com, New Orleans Historical, TheWrap and Wikipedia's summary of Goreau's biography. The cause of death and the cardiac sarcoidosis interpretation are R; everything clinical is synthetic. |
| safe messaging review | not_started | No mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Weight is recorded as measured, without comment on her body. Her death is recorded once, without detail. No relative, spouse, colleague or historical physician is given a role in the modern episode. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.